Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6346 to 6360 of 9045 results

  1. Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in people with pancreatic cancer and cachexia or pre-cachexia, to compare cachexia assessment methods and anti-cachexia interventions with standard care.

    Recommendation ID NG85/2 Question Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in

  2. What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell lung cancer following multimodality treatment including surgery?

    Recommendation ID NG122/1 Question What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell

  3. Research on the safety and efficacy of superior capsular augmentation for massive rotator cuff tears should address patient selection, type of graft and technique used,long-term outcomes including shoulder function, and patient-reported outcome measures.

    Recommendation ID IPG619/1 Question Research on the safety and efficacy of superior capsular augmentation for massive rotator cuff tears

  4. Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people with high-grade transformation of follicular lymphoma, which biological and clinical factors predict good outcomes with immunochemotherapy alone?

    Recommendation ID NG52/2 Question Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people

  5. Radiotherapy in first-line treatment of diffuse large B-cell lymphoma:- In people presenting with diffuse large B-cell lymphoma and sites of bulky disease, are outcomes improved by radiotherapy to those sites following a full course of chemotherapy?

    Recommendation ID NG52/3 Question Radiotherapy in first-line treatment of diffuse large B-cell lymphoma:- In people presenting with diffuse

  6. Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

    Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 babies' hearing so far with potential to prevent hearing loss in 200 babies annually.

  7. NICE enables groups and organisations to work together on their response to our online public consultations

    New functionality for online collaboration on consultations, enables groups or organisations to submit a joined-up response.

  8. Neonatal infection guidance updated to allow home antibiotic treatment for some babies

    We’ve recommended that newborn babies receiving antibiotics in hospital could potentially switch to oral antibiotics and be cared for at home if they are doing well and responding to treatment.

  9. Treating babies at home with oral antibiotics

    Home News Podcasts Treating babies at home with oral antibiotics Podcasts 27 May 2026 Listen About this episode In this episode we discuss

  10. First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer

    The treatment uses a targeted therapy that seeks out a specific protein found on the surface of cancer cells and delivers a cancer-killing medicine directly to them.

  11. NICE issues new guidance on 'artificial pancreas' technology for pregnant women with type 1 diabetes

    Women with type 1 diabetes who are pregnant or planning a pregnancy should be offered a pregnancy-specific 'artificial pancreas' device. That is the recommendation in draft guidance published today by NICE.

  12. Why flexibility is built into everything we do at NICE Advice

    No two products are the same, so no two NICE Advice projects should be either. Andrew Walsh explains how NICE Advice adapts its services to fit your situation.

  13. 5 tips to help get your healthtech product to market, fast

    Our associate director of NICE Advice outlines his top tips for healthtech companies, helping them chart a clear path from innovation to NHS adoption.